| 301.81 6.81 (2.31%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 370.37 | 1-year : | 432.59 |
| Resists | First : | 317.1 | Second : | 370.37 |
| Pivot price | 301.58 |
|||
| Supports | First : | 288.46 | Second : | 270.76 |
| MAs | MA(5) : | 298.75  |
MA(20) : | 296.24 |
| MA(100) : | 283.44 |
MA(250) : | 234.16 |
|
| MACD | MACD : | 2.9 |
Signal : | 3.5 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 51.4 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 326.63 | Low : | 175.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LGND ] has closed below upper band by 49.2%. Bollinger Bands are 26.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 305.06 - 306.23 | 306.23 - 307.58 |
| Low: | 291.16 - 292.4 | 292.4 - 293.84 |
| Close: | 299.46 - 301.49 | 301.49 - 303.82 |
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Wed, 07 Oct 2026
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Wed, 07 Oct 2026
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Tue, 29 Sep 2026
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance
Sun, 27 Sep 2026
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones - Yahoo Finance
Fri, 25 Sep 2026
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation (LGND:NASDAQ) - Seeking Alpha
Tue, 22 Sep 2026
How Ligand Pharmaceuticals Incorporated (LGND) Affects Rotational Strategy Timing - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 116 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 1,920 (K) |
| EPS | 9.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 48.56 |
| Profit Margin | 67.8 % |
| Operating Margin | 13.4 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 21.9 % |
| Qtrly Rev. Growth | 33.7 % |
| Gross Profit (p.s.) | 11.83 |
| Sales Per Share | 14.57 |
| EBITDA (p.s.) | 6.67 |
| Qtrly Earnings Growth | 825 % |
| Operating Cash Flow | 132 (M) |
| Levered Free Cash Flow | 140 (M) |
| PE Ratio | 31.08 |
| PEG Ratio | 1.5 |
| Price to Book value | 6.21 |
| Price to Sales | 20.71 |
| Price to Cash Flow | 45.69 |
| Dividend | 9.35 |
| Forward Dividend | 0 |
| Dividend Yield | 3.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|